Victory Capital Management
TXG icon

Victory Capital Management’s 10x Genomics TXG Stock Holding History

Victory Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$500K Buy
13,041
+148
+1% +$3.88K ﹤0.01% 2076
2026
Q1 		$274K Sell
12,893
-9
-0.1% -$180 ﹤0.01% 2140
2025
Q4 		$210K Buy
12,902
+186
+1% +$2.81K ﹤0.01% 2194
2025
Q3 		$149K Buy
12,716
+379
+3% +$4.94K ﹤0.01% 2252
2025
Q2 		$143K Buy
12,337
+101
+0.8% +$921 ﹤0.01% 2295
2025
Q1 		$107K Sell
12,236
-102
-0.8% -$1.29K ﹤0.01% 2303
2024
Q4 		$177K Sell
12,338
-299
-2% -$4.72K ﹤0.01% 2261
2024
Q3 		$285K Sell
12,637
-91
-0.7% -$1.88K ﹤0.01% 2149
2024
Q2 		$248K Sell
12,728
-203
-2% -$5.32K ﹤0.01% 2150
2024
Q1 		$485K Buy
12,931
+193
+2% +$8.48K ﹤0.01% 1991
2023
Q4 		$713K Buy
12,738
+2,515
+25% +$109K ﹤0.01% 1862
2023
Q3 		$422K Sell
10,223
-16,261
-61% -$846K ﹤0.01% 2038
2023
Q2 		$1.48M Sell
26,484
-1,241
-4% -$67.2K ﹤0.01% 1500
2023
Q1 		$1.55M Buy
27,725
+18,017
+186% +$841K ﹤0.01% 1481
2022
Q4 		$354K Sell
9,708
-5
-0.1% -$163 ﹤0.01% 2122
2022
Q3 		$277K Buy
+9,713
New +$370K ﹤0.01% 2277
2022
Q1 		– Sell
-23,560
Closed -$3.51M – 2811
2021
Q4 		$3.51M Sell
23,560
-21,455
-48% -$3.29M ﹤0.01% 1405
2021
Q3 		$6.55M Sell
45,015
-8,584
-16% -$1.47M 0.01% 1247
2021
Q2 		$10.5M Sell
53,599
-124,652
-70% -$22.6M 0.01% 1108
2021
Q1 		$32.3M Sell
178,251
-2,381
-1% -$411K 0.03% 734
2020
Q4 		$25.6M Sell
180,632
-23,584
-12% -$3.42M 0.03% 776
2020
Q3 		$25.5M Sell
204,216
-27,053
-12% -$2.84M 0.03% 691
2020
Q2 		$20.7M Sell
231,269
-126,970
-35% -$9.89M 0.03% 765
2020
Q1 		$22.3M Sell
358,239
-96,655
-21% -$7.54M 0.04% 617
2019
Q4 		$34.7M Sell
454,894
-106,780
-19% -$6.42M 0.04% 622
2019
Q3 		$28.3M Buy
+561,674
New +$31.1M 0.04% 665

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management's TXG Position: Q2 2026 in Review

Victory Capital Management increased its 10x Genomics (TXG) stake by 1.1% in Q2 2026, buying an estimated $3.88K and bringing the position to 13,041 shares worth $500K. The position accounts for ﹤0.01% of the portfolio, ranked #2076.

Victory Capital Management first reported a position in TXG in Q3 2019 and has held it in 26 quarters since. The position peaked at $34.7M in Q4 2019. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Victory Capital Management held 13,041 shares of 10x Genomics worth $500K as of Q2 2026.
  • Victory Capital Management bought 148 10x Genomics shares in Q2 2026, an estimated $3.88K.
  • 10x Genomics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2076 holding.
  • Victory Capital Management first reported a position in 10x Genomics in Q3 2019 and has held it in 26 quarters since.
  • Victory Capital Management's 10x Genomics position peaked at $34.7M in Q4 2019.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.